Table 3.

Best overall response per RECIST or PCWG3 in patients treated with BAY 1895344 monotherapy

Total(N = 21)3 days on/4 days off schedule(n = 17)Doses ≥40 mg BID 3 days on/4 days off(n = 13)Patients with ATM loss and/or ATM mutation(n = 11)
Best responsea, n (%)
 Complete response0000
 Partial response4 (19.0)4 (23.5)4 (30.8)4 (36.4)
 Stable disease8 (38.1)6 (35.3)5 (38.5)3 (27.3)
 Progressive diseaseb9 (42.9)7 (41.2)4 (30.8)4 (36.4)
Objective response rate, n (%)4 (19.0)4 (23.5)4 (30.8)4 (36.4)
Disease control rate, n (%)12 (57.1)10 (58.8)9 (69.2)7 (63.6)
Median duration of response, days (range)315.5 (246–357)315.5 (246–357)315.5 (246–357)315.5 (246–357)
Median duration of stable disease, days (range)89 (51–378)89 (51–378)86 (51–371)86 (51–127)
Median time to response, days (range)78 (49–211)78 (49–211)78 (49–211)78 (49–211)
  • Abbreviations: BID, twice daily; PCWG3, Prostate Cancer Working Group 3.

  • a1 patient receiving treatment on the 3 days on/4 days off schedule did not have a post-baseline tumor assessment and therefore was not evaluable for best response.

  • b2 patients who achieved stable disease as RECIST best response had investigator-assessed clinical disease progression at the same time point and were therefore reported as having progressive disease.